Development of a CRISPR-Cas9-Based Cellular Model for SGCB Gene Mutation: A Platform for Investigating Gene Therapy Strategies in LGMD2E

Read full text Summarise with VIRAT
Authors: Zahra Farshchian Yazdi, Shahrzad Roshannezhad, Atieh Eslahi, Farzaneh Lal Alizadeh, Shima Farrokhi, Mohammad Hasan Sheikhha, Majid Mojarrad
Cited by: 0
References: 41

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E) is one of the most prevalent phenotypes within the limb-girdle muscular dystrophies (LGMDs). This myopathy is caused by pathogenic mutations in the SGCB gene, which encodes β-type sarcoglycan. LGMD2E is recognized as the most prevalent sarcoglycanopathy among the Iranian population specially within the Baloch ethnic group. To develop innovative gene therapy strategies based on accessible gene delivery and gene editing techniques, it is essential to have a cell line harboring genomic mutations in the SGCB gene. These cell models are crucial for the preliminary evaluation of the efficacy of gene-editing-based methods. In this study, we utilized the clustered regularly interspaced short palindromic repeats (CRISPR) system and the approach of inducing indel mutations to generate an HEK-293T cell model harboring a frameshift mutation in SGCB gene. Methods Two distinct SGCB exon 2 targeting single guide RNAs (sgRNAs) were cloned into PX458 plasmids containing spCas9, and recombinant plasmids were transduced into HEK293T cells. The mutagenesis efficiency was evaluated using the TIDE program on Sanger sequencing data of transduced cells. Mutated cell clones were obtained through serial dilution techniques. Results Our results demonstrated the substantial efficacy of the CRISPR-Cas9 system in inducing mutations within the SGCB gene. This capability presents significant potential for precise editing of the SGCB gene in muscular cells, thereby establishing a robust cellular model for LGMD2E gene-editing strategies. Conclusions The application of CRISPR-Cas9 technology in this study highlights its potential for targeted gene editing in LGMD2E research. These findings pave the way for further investigations into the development of precision therapy for LGMD2E, ultimately contributing to the development of effective therapeutic strategies.

Fields of Study & Subjects

CRISPR and Genetic Engineering Muscle Physiology and Disorders Virus-based gene therapy research

Publication details

Journal / source
Research Square
Publication date
31 March 2026
Language
EN
Document type
Preprint